Journal
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
Volume 3, Issue 1, Pages 38-43Publisher
WILEY
DOI: 10.1002/cjp2.56
Keywords
breast cancer; tamoxifen; tumour stroma; PDGFR beta
Categories
Funding
- Swedish Research Council (STARGET network)
- Breast Cancer Theme Center (BRECT) at Karolinska Institutet
- Swedish Cancer Society
- Radiumhemmet
- Stockholm County Council (ALF)
- Karolinska Institutet-Astra Zeneca
- Knut and Alice Wallenberg grant
- Swedish Breast Cancer Association
- Percy Falks stiftelse for forskning betraffande prostatacancer och brostcancer
Ask authors/readers for more resources
Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signalling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFR beta is an important regulator of fibroblasts. Experimental studies have linked PDGFR beta-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFR beta-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomised studies analysing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFR beta, which was not observed in the group with high stromal PDGFR beta. In general terms these findings provide novel evidence, derived from analyses of randomised clinical studies, of response-predictive capacity of a marker-defined subset of CAFs and, more specifically, identify stromal PDGFR beta as a marker related to tamoxifen benefit in early breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available